DRI Capital Acquires Rights to Nanogen Royalties

Mar 31, 2008

NEW YORK (GenomeWeb News) – DRI Capital will pay Nanogen $10 million for the rights to all future royalties under a licensing agreement between Nanogen and Applied Biosystems.

According to a joint announcement from the firms, DRI Capital will receive royalties related to Nanogen’s minor groove binder technology, which was licensed by ABI for use in certain TaqMan products. The MGB technology is used for the design of oligonucleotide probes.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Testing, Testing for Mutations

US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.

Hide, Nessie, Hide

A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.

Even More Variety

The New York Times writes about the appearance of mosaicism in healthy people.

This Week in PNAS

In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.

Main menu